Mehedinti Roxana Cristina

Dr. Mehedinti Roxana Cristina


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2026 in Cells
Verified
Journal Article
Open access
PDF file
Catalin Bogdan SatalaCatalin Bogdan Satala
Catalin Bogdan Satala
Alina Mihaela GURĂUAlina Mihaela GURĂU
Alina Mihaela GURĂU
DMDaniela Mihalache
Daniela Mihalache
GPGabriela Patrichi
Gabriela Patrichi
MCMehedinti Roxana Cristina
Mehedinti Roxana Cristina
GGGabriela Gurau
Gabriela Gurau
Gastric cancer peritoneal metastasis is not simply an extension of the primary tumor into the abdominal cavity. It represents a biologically distinct disease context shaped by interactions between disseminated tumor cells, peritoneal fluid, mesothelial surfaces, submesothelial stroma, extracellular matrix, immune populations, and malignant ascites. In this narrative review, we examine peritoneal metastasis as a transition between three related but physiologically different states: the primary gastric tumor, free-floating tumor cells or spheroids in the peritoneal fluid, and established mesothelial or submesothelial metastatic implants. We discuss how tumor cells acquire dissemination competence in the primary tumor, survive detachment and fluid-phase stress, adhere to remodeled mesothelium, recruit stromal and immune support, and adapt to ascites-mediated signaling. We also review how the peritoneal niche may contribute to biomarker discordance, immune exclusion, therapeutic resistance, and limitations of conventional response assessment. Where relevant, we distinguish evidence derived directly from gastric cancer peritoneal metastasis from preclinical data, extrapolation from other peritoneal malignancies, and hypothesis-generating interpretation. Finally, we summarize practical implications for tissue sampling, ascites and lavage analysis, biomarker interpretation, translational modeling, and peritoneal-directed therapeutic strategies. A clearer understanding of the biological divergence between the primary tumor, the fluid-phase compartment, and peritoneal implants may improve the study and clinical management of gastric cancer peritoneal metastasis.

6 June 2026 in Cancers
Verified
Journal Article
Open access
PDF file
Catalin Bogdan SatalaCatalin Bogdan Satala
Catalin Bogdan Satala
GGGabriela Gurau
Gabriela Gurau
GPGabriela Patrichi
Gabriela Patrichi
Alina Mihaela GURĂUAlina Mihaela GURĂU
Alina Mihaela GURĂU
MCMehedinti Roxana Cristina
Mehedinti Roxana Cristina
DMDaniela Mihalache
Daniela Mihalache
Fibroblast growth factor receptor 2b (FGFR2b) has become an increasingly important therapeutic target in gastric and gastroesophageal junction cancer, particularly with the clinical development of FGFR2b-directed antibody therapy. However, its translation into routine treatment selection is not straightforward. FGFR2b is usually assessed as a protein biomarker by immunohistochemistry, and a positive result may reflect different biological situations depending on staining intensity, percentage of positive tumor cells, sample type and spatial distribution. In addition, FGFR2b protein expression, FGFR2 amplification, transcript-level activity and true pathway dependency are related but not interchangeable. This review examines FGFR2b-positive gastric cancer from the perspective of biomarker reliability rather than target presence alone. We discuss the biological basis of FGFR2b targeting, the reasons for variability in reported positivity rates, the implications of intratumoral and inter-lesion heterogeneity, the current clinical evidence for FGFR2b-directed and broader FGFR-targeted approaches, and the emerging challenges of safety, resistance and treatment sequencing. Particular attention is given to the gap between detecting FGFR2b and identifying tumors in which this target is sufficiently expressed, representative and biologically relevant to guide therapy. We also consider how FGFR2b should be interpreted alongside HER2, CLDN18.2, immune biomarkers and other receptor tyrosine kinase alterations. As FGFR2b-directed strategies move forward, their success will depend not only on drug efficacy, but also on standardized testing, careful reporting, and selective reassessment when disease biology changes. FGFR2b therefore offers a useful model for how protein biomarkers can be developed in gastric cancer: not as isolated positive-or-negative labels, but as clinically interpreted variables within a changing therapeutic landscape.

14 May 2026 in Medicina
Verified
Journal Article
Open access
PDF file
MCMehedinti Roxana Cristina
Mehedinti Roxana Cristina
DCDorin Ioan Cocoș
Dorin Ioan Cocoș
Ada StefanescuAda Stefanescu
Ada Stefanescu
MMMădălina Nicoleta Matei
Mădălina Nicoleta Matei
GPGabriel Valeriu Popa
Gabriel Valeriu Popa
DTDana Tutunaru
Dana Tutunaru
Background and Objectives: Prolonged contact between oral mucosa and dental amalgam restorations may influence local epithelial homeostasis, but the remodeling profile of clinically non-dysplastic mucosa exposed to long-standing amalgam remains insufficiently characterized. This study aimed to evaluate histopathological changes and CK19, Ki67, and p53 expression in the oral mucosa adjacent to long-term amalgam restorations. Materials and Methods: A retrospective observational analysis was performed on 108 oral mucosal specimens, including 78 samples in direct contact with amalgam restorations and 30 non-exposed controls. Exposed cases were grouped according to contact duration: 5–10 years, 11–20 years, and ≥21 years. Histopathological parameters and immunohistochemical expression of CK19, Ki67, and p53 were semi-quantitatively assessed, and an exploratory Integrated Epithelial Remodeling Score was calculated. Results: Longer amalgam exposure was significantly associated with increased inflammatory infiltrate, basal hyperplasia, acanthosis, fibrosis, suprabasal CK19 redistribution, and higher Ki67 labeling indices. The Integrated Epithelial Remodeling Score differed significantly among exposure groups, with higher values in intermediate- and long-duration exposure categories. p53 expression showed statistically detectable but heterogeneous variation. No epithelial dysplasia was observed. Conclusions: Long-term contact with dental amalgam restorations was associated with a coordinated, non-dysplastic remodeling phenotype of the oral mucosa. Given the age imbalance across exposure duration groups, these findings should be interpreted as exposure-associated patterns rather than evidence of a direct causal effect. Because no comparison group exposed to other restorative materials was included, material-specificity for dental amalgam cannot be inferred. In architecturally preserved mucosa, suprabasal CK19 expression may reflect adaptive epithelial plasticity rather than preneoplastic transformation.

21 May 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
Catalin Bogdan SatalaCatalin Bogdan Satala
Catalin Bogdan Satala
Alina Mihaela GURĂUAlina Mihaela GURĂU
Alina Mihaela GURĂU
GPGabriela Patrichi
Gabriela Patrichi
MCMehedinti Roxana Cristina
Mehedinti Roxana Cristina
ALAndy Radu Leibovici
Andy Radu Leibovici
GGGabriela Gurau
Gabriela Gurau
Neuroendocrine differentiation in tumors of the female genital tract is an uncommon but diagnostically consequential finding. Its interpretation is challenging because neuroendocrine marker expression does not necessarily define a neuroendocrine neoplasm. Focal or aberrant staining for synaptophysin, chromogranin A, CD56 or INSM1 may occur in otherwise conventional gynecologic carcinomas, whereas true poorly differentiated neuroendocrine carcinomas represent aggressive tumors with distinct prognostic and therapeutic implications. This narrative review examines neuroendocrine differentiation across the cervix, endometrium, ovary, vagina and vulva from an integrated clinicopathologic perspective. We emphasize that neuroendocrine differentiation should be approached as a diagnostic and biological spectrum, ranging from incidental immunophenotypic expression to carcinoma with neuroendocrine differentiation, mixed neuroendocrine/non-neuroendocrine tumors, well-differentiated neuroendocrine tumors and poorly differentiated neuroendocrine carcinomas. Morphology remains the diagnostic anchor, while immunohistochemistry, molecular context and clinicoradiologic correlation refine classification and help exclude mimics or metastatic disease. Site-specific interpretation is essential: cervical neuroendocrine carcinoma is commonly HPV-associated and clinically aggressive; endometrial tumors require integration with p53, mismatch repair, POLE and SWI/SNF-related contexts; ovarian lesions demand distinction between primary well-differentiated neuroendocrine tumors, poorly differentiated carcinomas and metastases; and vaginal or vulvar tumors require careful exclusion of adjacent extension, cutaneous mimics and extragenital primaries. We propose a practical diagnostic framework that separates incidental marker expression from clinically meaningful neuroendocrine differentiation and links this distinction to reporting, prognosis and treatment. The central diagnostic question is not whether neuroendocrine markers are expressed but whether their expression defines a morphologically, biologically and clinically meaningful tumor category.

5 May 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
Catalin Bogdan SatalaCatalin Bogdan Satala
Catalin Bogdan Satala
Alina Mihaela GURĂUAlina Mihaela GURĂU
Alina Mihaela GURĂU
GPGabriela Patrichi
Gabriela Patrichi
MCMehedinti Roxana Cristina
Mehedinti Roxana Cristina
GGGabriela Gurau
Gabriela Gurau
Neuroendocrine differentiation in tumors of the female genital tract is an uncommon but diagnostically consequential finding. Its interpretation is challenging because neuroendocrine marker expression does not necessarily define a neuroendocrine neoplasm. Focal or aberrant staining for synaptophysin, chromogranin A, CD56 or INSM1 may occur in otherwise conventional gynecologic carcinomas, whereas true poorly differentiated neuroendocrine carcinomas represent aggressive tumors with distinct prognostic and therapeutic implications. This narrative review examines neuroendocrine differentiation across the cervix, endometrium, ovary, vagina and vulva from an integrated clinicopathologic perspective. We emphasize that neuroendocrine differentiation should be approached as a diagnostic and biological spectrum, ranging from incidental immunophenotypic expression to carcinoma with neuroendocrine differentiation, mixed neuroendocrine/non-neuroendocrine tumors, well-differentiated neuroendocrine tumors and poorly differentiated neuroendocrine carcinomas. Morphology remains the diagnostic anchor, while immunohistochemistry, molecular context and clinicoradiologic correlation refine classification and help exclude mimics or metastatic disease. Site-specific interpretation is essential: cervical neuroendocrine car-cinoma is commonly HPV-associated and clinically aggressive; endometrial tumors require integration with p53, mismatch repair, POLE and SWI/SNF-related contexts; ovarian lesions demand distinction between primary well-differentiated neuroendocrine tumors, poorly differentiated carcinomas and metastases; and vaginal or vulvar tumors require careful exclusion of adjacent extension, cutaneous mimics and extragenital primaries. We propose a practical diagnostic framework that separates incidental marker expression from clinically meaningful neuroendocrine differentiation and links this distinction to reporting, prognosis and treatment. The central diagnostic question is not whether neuroendocrine markers are expressed, but whether their expression defines a morphologically, biologically and clinically meaningful tumor category.

9 June 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
AOAndreea Onofrei
Andreea Onofrei
GGGabriela Gurau
Gabriela Gurau
GPGabriela Patrichi
Gabriela Patrichi
Alina Mihaela GURĂUAlina Mihaela GURĂU
Alina Mihaela GURĂU
MCMehedinti Roxana Cristina
Mehedinti Roxana Cristina
Catalin Bogdan SatalaCatalin Bogdan Satala
Catalin Bogdan Satala
Cervical neuroendocrine carcinoma (NECC) is a rare but highly aggressive cervical malignancy, accounting for approximately 1% of invasive cervical cancers. Diagnosis is challenging because NECC overlaps morphologically with other poorly differentiated cervical and metastatic tumors, may show crush artifact in small biopsies, and can display variable expression of conventional neuroendocrine markers. This narrative review provides a practical synthesis of the histopathological, immunohistochemical, molecular, and clinical features of NECC, with emphasis on diagnostic pitfalls and differential diagnosis. Recent English-language literature on cervical neuroendocrine carcinoma was reviewed and qualitatively integrated, focusing on morphology, immunohistochemistry, HPV association, molecular alterations, prognosis, and management-relevant diagnostic issues. Accurate diagnosis requires integration of morphology, epithelial differentiation, neuroendocrine marker expression, HPV-related context, and clinic-radiological correlation. Useful markers include broad-spectrum cytokeratins, synaptophysin, chromogranin A, CD56, INSM1, p16, and Ki-67, with additional markers selected according to the differential diagnosis. Diffuse block-type p16 expression and high-risk HPV detection support a cervical HPV-associated origin but are not specific for neuroendocrine differentiation. Molecular studies show frequent association with HPV18 and recurrent alterations involving PI3K/AKT, RAS/MAPK, and TP53-related pathways, although these findings remain insufficiently validated for routine prognostic or therapeutic stratification. NECC requires early recognition and a multimodal diagnostic approach because of its aggressive behavior and poor prognosis. A practical, stepwise integration of morphology, immunohistochemistry, molecular findings, and clinical–radiological data may improve diagnostic consistency and support multidisciplinary management.